epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLC10.17749/2077-8333.2018.10.1.052-062epilepsia-392Research ArticleEXPERIMENTAL EPILEPTOLOGYЭКСПЕРИМЕНТАЛЬНАЯ ЭПИЛЕПТОЛОГИЯEFFECTS OF LEVETINOL ON EPILEPTIFORM ACTIVITY OF THE BRAIN IN RATS WITH COBALT-INDUCED EPILEPSYОСОБЕННОСТИ ДЕЙСТВИЯ ЛЕВЕТИНОЛА НА РАЗВИТИЕ СУДОРОЖНОЙ АКТИВНОСТИ У КРЫС С КОБАЛЬТ-ИНДУЦИРОВАННОЙ ХРОНИЧЕСКОЙ ЭПИЛЕПСИЕЙhttps://orcid.org/0000-0001-9139-2334ЛитвиноваС. А.LitvinovaS. A.

к.б.н., ведущий научный сотрудник лаборатории психофармакологии, 

ул. Балтийская, 8, 125315 Москва

8 Baltijskaja Str., 125315 Moscow

sa_litvinova@mail.ruВоронинаТ. А.VoroninaT. A.

профессор, д.м.н., руководитель лаборатории психофармакологии,

ул. Балтийская, 8, 125315 Москва

8 Baltijskaja Str., 125315 Moscow

voroninata38@gmail.comНеробковаЛ. Н.NerobkovaL. N.

к.б.н., старший научный сотрудник лаборатории психофармакологии,

ул. Балтийская, 8, 125315 Москва

8 Baltijskaja Str., 125315 Moscow

Ln_Nerobkova@mail.ruКутеповаИ. С.KutepovaI. S.

аспирант,

ул. Балтийская, 8, 125315 Москва

8 Baltijskaja Str., 125315 Moscow

shatalovo.100@mail.ruАвакянГ. Г.AvakyanG. G.

к.м.н., ассистент кафедры неврологии, нейрохирургии и медицинской генетики,

ул. Островитянова, 1, Москва 117997

1 Ostrovityanova Str., Moscow 117997

avakyan_georgy@mail.ruАвакянГ. Н.AvakyanG. N.

д.м.н., профессор кафедры неврологии, нейрохирургии и медицинской генетики,

ул. Островитянова, 1, Москва 117997

1 Ostrovityanova Str., Moscow 117997

gavakyan@yandex.ruФедеральное государственное бюджетное научное учреждение «НИИ Фармакологии им. В.В. Закусова»РоссияV.V. Zakusov Institute of PharmacologyRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияN. I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian Federation2018310520181015262Copyright © Litvinova S.A., Voronina T.A., Nerobkova L.N., Kutepova I.S., Avakyan G.G., Avakyan G.N., 20182018Литвинова С.А., Воронина Т.А., Неробкова Л.Н., Кутепова И.С., Авакян Г.Г., Авакян Г.Н.Litvinova S.A., Voronina T.A., Nerobkova L.N., Kutepova I.S., Avakyan G.G., Avakyan G.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/392

The aim of this study was to evaluate the anti-seizure effect of Levetinol tablet (Geropharm) on the cobalt-induced chronic epilepsy.

Materials and methods

Materials and methods. A model of cobalt-induced epilepsy was created by applying cobalt powder to the sensorimotor zone of the rat cortex. The effects of Levetinol were studied at the early stage of the epileptic system (ES) formation (on day 2 after the cobalt application), and then at the stage of fully developed ES (on day 6 after the cobalt application).

Results

Results. The present study showed that at the early stage of ES development, Levetinol at doses of 50 and 200 mg/kg had no statistically significant effect on the development of paroxysmal activity in both primary and secondary epileptic foci: in the ipsi- and contralateral cortex, hypothalamus and hippocampus. On day 6 of the cobalt-induced epilepsy, a significant suppression of paroxysmal activity in the above structures of the brain was observed with the administration of Levetinol at a dose of 200 mg/kg. The most pronounced anti-seizure effect was found in the hippocampus; that was expressed in normalization of the bioelectrical activity and appearance of the regular theta rhythm.

Conclusion

Conclusion. The effects of Levetinol are largely manifested in the hippocampal foci of epileptiform activity and, to a lesser extent, in the cortical foci. 

Целью исследования явилось изучение противосудорожного эффекта таблетированной лекарственной формы препарата Леветинола (Герофарм) на модели кобальт-индуцированной хронической эпилепсии.

Материалы и методы

Материалы и методы. Модель кобальт-индуцированной эпилепсии вызывали аппликацией кобальта на сенсомоторную зону коры крысы. Эффекты Леветинола изучали на начальной стадии развития эпилептической системы (ЭС) – 2-й день после аппликации кобальта и на фоне генерализации пароксизмальной активности – 6-й день после аппликации кобальта.

Результаты

Результаты. проведенные исследования показали, что в начальной стадии развития ЭС Леветинол в дозах 50 и 200 мг/кг не оказывал статистически достоверного влияния на развитие пароксизмальной активности как в первичных, так и во вторичных эпилептических очагах: в ипси-, контралатеральной коре, гипоталамусе и гиппокампе. Значительное подавление пароксизмальной активности во всех исследуемых структурах мозга крыс с кобальтовой эпилепсией наблюдалось при введении Леветинола в дозе 200 мг/кг на 6-й день развития ЭС. При этом наибольшая выраженность противосудорожного эффекта проявлялась в гиппокампограммах, что выражалось в нормализации биоэлектрической активности и появлении регулярного тета-ритма.

Заключение

Заключение. Эффекты Леветинола в большей степени направлены на гиппокампальные очаги эпилептиформной активности и в меньшей степени – на корковые очаги. 

леветирацетамЛеветинолэпилепсияЭЭГпароксизмальная активностькобальт-индуцированная эпилепсиякрысыLevetiracetamLevetinolepilepsyseizuresEEGparoxysmal activitycobalt-induced epilepsyratsReferencesDe Smedt T., Raedt R., Vonck K., Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007; 13: 57-78.De Smedt T., Raedt R., Vonck K., Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007; 13: 57-78.Gower A. J., Hirsch E, Boehrer A et al. Effects of Levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995; 22 (3): 207-13.Gower A. J., Hirsch E, Boehrer A et al. Effects of Levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995; 22 (3): 207-13.Klitgaard H., Matagne H., Gobert J., Wulfert E. Evidence for a unique profile of Levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998; 353: 191-206.Klitgaard H., Matagne H., Gobert J., Wulfert E. Evidence for a unique profile of Levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998; 353: 191-206.Раевский К.С., Маликова Л.А., Калинин В.В. Нейрональные и нейрохимические механизмы действия нового противоэпилептического средства леветирацетама. Экспериментальная и клиническая фармакология. 2007; 70 (2): 70-74.Raevskii K.S., Malikova L.A., Kalinin V.V. Ek sperimental’naya i klinicheskaya farmakologiya (in Russian). 2007; 70 (2): 70-74.Loscher W., Hönack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant Levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 1998; 284 (2): 474-9.Loscher W., Hönack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant Levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 1998; 284 (2): 474-9.Mohanraj R., Parker P.G., Stephen L. J., Brodie M. J. Levetiracetam in refractory epilepsy: a prospective obsevational study. Seizure. 2005; 14: 23-27.Mohanraj R., Parker P.G., Stephen L. J., Brodie M. J. Levetiracetam in refractory epilepsy: a prospective obsevational study. Seizure. 2005; 14: 23-27.Palma E., Ragozzino D., Di Angelantonio S., Mascia A. et al. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia. 2007; 48: 1842-49.Palma E., Ragozzino D., Di Angelantonio S., Mascia A. et al. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia. 2007; 48: 1842-49.Rigo J.M., Hans G., Nguyen L., et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002; 136: 659-672.Rigo J.M., Hans G., Nguyen L., et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002; 136: 659-672.Wakita M., Kotani N., Kogure K., Akaike N. Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn²-dependent GABA type A receptor-mediated presynaptic modulation. J Pharmacol Exp Ther. 2014; 348 (2): 246-59.Wakita M., Kotani N., Kogure K., Akaike N. Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn²-dependent GABA type A receptor-mediated presynaptic modulation. J Pharmacol Exp Ther. 2014; 348 (2): 246-59.Gillard M., Fuks B., Michel P., Vertongen P., Massingham R., Chatelain P. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol. 2003; 478: 1-910.1016.Gillard M., Fuks B., Michel P., Vertongen P., Massingham R., Chatelain P. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol. 2003; 478: 1-910.1016.Gillard M., Chatelain P., Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006; 536: 102-810.Gillard M., Chatelain P., Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006; 536: 102-810.Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P. et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004; 101: 9861-610.Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P. et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004; 101: 9861-610.Rainer S., Volynski K. E., Walker M.C. Is Levetiracetam Different from Other Antiepileptic Drugs? Levetiracetam and its Cellular Mechanism of Action in Epilepsy Revisited. Ther Adv Neurol Disord. 2008; 1(1): 13-24.Rainer S., Volynski K. E., Walker M.C. Is Levetiracetam Different from Other Antiepileptic Drugs? Levetiracetam and its Cellular Mechanism of Action in Epilepsy Revisited. Ther Adv Neurol Disord. 2008; 1(1): 13-24.Stephen L. J., Kelly K., Parker P., Brodie M. J. Levetiracetam monotherapy-outcomes from an epilepsy clinic. Seizure. 2011; 20 (7): 554-7.Stephen L. J., Kelly K., Parker P., Brodie M. J. Levetiracetam monotherapyoutcomes from an epilepsy clinic. Seizure. 2011; 20 (7): 554-7.Bialer M., Johannessen S. I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 2010; 92: 89-12.Bialer M., Johannessen S. I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 2010; 92: 89-12.Angehagen M., Margineanu D.G., BenMenachem E., Rönnbäck L., Hansson E., Klitgaard H. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport. 2003; 14: 471-475Angehagen M., Margineanu D.G., BenMenachem E., Rönnbäck L., Hansson E., Klitgaard H. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport. 2003; 14: 471-475Carunchio I., Pieri M., Ciotti M. T., Albo F., Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia. 2007; 48: 654-662.Carunchio I., Pieri M., Ciotti M. T., Albo F., Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia. 2007; 48: 654-662.Cataldi M., Lariccia V., Secondo A., di Renzo G., Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther. 2005; 313: 720-730.Cataldi M., Lariccia V., Secondo A., di Renzo G., Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther. 2005; 313: 720-730.Löscher W., Hönack D. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam. Epilepsia. 2000; 41: 1499-1506.Löscher W., Hönack D. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam. Epilepsia. 2000; 41: 1499-1506.Zhang Z. J., Xing G.Q., Russell S., Obeng K., Post R.M. Unidirectional cross-tolerance from levetiracetam to carbamazepine in amygdala-kindled seizures. Epilepsia. 2003; 44 (12): 1487-93.Zhang Z. J., Xing G.Q., Russell S., Obeng K., Post R.M. Unidirectional cross-tolerance from levetiracetam to carbamazepine in amygdala-kindled seizures. Epilepsia. 2003; 44 (12): 1487-93.Van Vliet E.A., van Schaik R., Edelbroek P.M. et al. Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia. 2008; 49 (7): 1151-9.Van Vliet E.A., van Schaik R., Edelbroek P.M. et al. Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia. 2008; 49 (7): 1151-9.Friedman D., French J.A. Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. Neurology. 2006 Feb 28; 66 (4): 590-1.Friedman D., French J.A. Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. Neurology. 2006 Feb 28; 66 (4): 590-1.Packer R.M.A., Nye G., Porter S. E., Volk H.A. Assessment into the usage of levetiracetam in a canine epilepsy clinic. BMC Veterinary Research. 2015; 11: 25.Packer R.M.A., Nye G., Porter S. E., Volk H.A. Assessment into the usage of levetiracetam in a canine epilepsy clinic. BMC Veterinary Research. 2015; 11: 25.Авакян Г.Н., Неробкова Л.Н., Воронина Т.А., Маркина Н.В., Митрофанов А.А. Влияние карбамазепина на структурно функциональные связи в развитии эпилептической системы. Экспериментальная и клиническая фармакология. 2002; 2: 7-10.Avakyan G.N., Nerobkova L.N., Voronina T.A., Markina N.V., Mitrofanov A. A. Eksperimental’naya i klinicheskaya farmakologiya (in Russian). 2002; 2: 7-10.Bregman F., Le Saux S., Trottier P., Chauvel L., Maurin Y. Chronic Cobaltinduced Epilepsy: Noradrenaline Ionophoresis and Adrenoceptor Binding Studies in the Rat Cerebral Cortex. J. Neural Transmission. 1985; 63: 109-118.Bregman F., Le Saux S., Trottier P., Chauvel L., Maurin Y. Chronic Cobaltinduced Epilepsy: Noradrenaline Ionophoresis and Adrenoceptor Binding Studies in the Rat Cerebral Cortex. J. Neural Transmission. 1985; 63: 109-118.Voronina T.A., Stoĭko M. I., Nerobkova L.N., Avakian G.N., Kraĭneva V.A. Effect of phenytoin on neurotoxin homocysteine thiolactone-induced convulsions and epileptic status in rats with cobalt-induced epilepsy. Eksp Klin Farmakol. 2002; 65 (1): 15-8.Voronina T.A., Stoĭko M. I., Nerobkova L.N., Avakian G.N., Kraĭneva V.A. Effect of phenytoin on neurotoxin homocysteine thiolactone-induced convulsions and epileptic status in rats with cobalt-induced epilepsy. Eksp Klin Farmakol (in Russian). 2002; 65 (1): 15-8.Walton N.Y., Treiman D.M. Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. Epilepsy Res. 1990; 5 (2): 165-8.Walton N.Y., Treiman D.M. Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. Epilepsy Res. 1990; 5 (2): 165-8.Walton N.Y., Treiman D.M. Valproic acid treatment of experimental status epilepticus. Epilepsy Res. 1992; 12 (3): 199-205.Walton N.Y., Treiman D.M. Valproic acid treatment of experimental status epilepticus. Epilepsy Res. 1992; 12 (3): 199-205.Walton N.Y., Jaing Q., Hyun B., Treiman D.M. Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res. 1996; 24 (1): 19-28.Walton N.Y., Jaing Q., Hyun B., Treiman D.M. Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res. 1996; 24 (1): 19-28.Воронина Т.А., Неробкова Л.Н. Методические указания по изучению противосудорожной активности фармакологических веществ. Руководство по проведению доклинических исследований лекарственных средств. М. 2012; 1 (14): 235-250.Voronina T.A., Nerobkova L.N. Methodical instructions for the study of anticonvulsant activity of pharmacological substances. A guide to preclinical drug research [Metodicheskie ukazaniya po izucheniyu protivosudorozhnoi aktivnosti farmakologicheskikh veshchestv. Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv (in Russian)]. Moscow. 2012; 1 (14): 235-250.Буреш Дж., Петрань М., Захар Д. Электрофизиологические методы исследования в биологии. М. 1964; 551.Buresh Dzh., Petran’ M., Zakhar D. Electrophysiological methods of research in biology [Elektrofiziologicheskie metody issledovaniya v biologii (in Russian)]. Moscow. 1964; 551.

The authors declare that there are no conflicts of interest present.